[Susceptibility of recent clinical isolates of Pseudomonas aeruginosa and Serratia marcescens to cefotaxime, ceftizoxime, cefmenoxime, latamoxef and cefsulodin in comparison with other beta-lactam antibiotics and aminoglycosides].
D000617:Aminoglycosides / Q000494:pharmacology; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D015281:Cefmenoxime; D002439:Cefotaxime / Q000031:analogs & derivatives / Q000494:pharmacology*; D002441:Cefsulodin; D015296:Ceftizoxime; D002511:Cephalosporins / Q000494:pharmacology; D002513:Cephamycins / Q000494:pharmacology; D004352:Drug Resistance, Microbial; D009070:Moxalactam; D011550:Pseudomonas aeruginosa / Q000187:drug effects*; D012706:Serratia marcescens / Q000187:drug effects*
D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; D002511:Cephalosporins; D002513:Cephamycins; D015296:Ceftizoxime; D015281:Cefmenoxime; D002439:Cefotaxime; D002441:Cefsulodin; D009070:Moxalactam